 |
| |
What's New?
 |
SAVE THE DATE! - June 30, 2008
posted April 2008
Third Annual Jerry D'Amato Charity Golf Outing
It's that time of year again to start thinking about warm weather, fun in the sun and supporting a great cause. In a spirit of hope to those facing the devastating disease of esophageal cancer and as a tribute to the great guy Jerry was, please join us for the third annual Jerry D'Amato Charity Golf Outing and fundraising event.
Thanks to the supporters of this fundraising event, a donation of over $40,000 has been given to the John's Hopkins Esophageal Cancer Research Center to help find a cure for the cancer that took Jerry and many others like him without warning. Your continued support gives hope to us all."
Check back soon for more details...
The Johns Hopkins Hospital Tops U.S. News & World Report's "HONOR ROLL" for the 17th Year in a row!
posted July 2007
THE JOHNS HOPKINS HOSPITAL TOPS U.S.NEWS & WORLD REPORT'S "HONOR ROLL" FOR THE 17th YEAR IN A ROW
For a detailed list of all rankings, go to the U.S. News and World Report.
The Johns Hopkins Hospital Tops U.S. News & World Report's "HONOR ROLL" for the 16th Year in a row!
posted July 2006
THE JOHNS HOPKINS HOSPITAL TOPS U.S.NEWS & WORLD REPORT'S "HONOR ROLL" FOR THE 16th YEAR IN A ROW
The Johns Hopkins Hospital has again earned the top spot as "Best of the Best" in U.S. News & World Report's annual Honor Roll of American hospitals, placing first in five of 16 ranked medical specialties and in the top four in 10 others. Only 14 hospitals nationwide made it to the Honor Roll this year out of 5,189 institutions graded.
This year's annual guide reports results of a survey of a hospital's reputation among a national sample of physicians, along with analysis of objective indicators such as death rates, technology, nurse staffing, service mix and discharge planning.
For a detailed list of all rankings, go to www.hopkinsmedicine.org or to the U.S. News and World Report.
The Johns Hopkins Hospital Tops U.S.News & World Report's "HONOR ROLL" For The 15th Year In A Row posted July 2005
For the 15th consecutive year, U.S. News & World Report's annual ranking of American hospitals has placed The Johns Hopkins Hospital at the top of the list.
The magazine's recognition is, as always, a tribute to the Hospital, its dedicated nurses and staff, the School of Medicine's faculty physicians and the community physicians whose contributions are significant.
As we endeavor to rebuild, renew, enrich and expand our services and facilities, and to assure our continued commitment to safety and excellence, such independent evaluations as these rankings are of growing value to patients, the public, referring physicians and insurers.
This year's annual guide ranked American medical centers in 17 specialties to identify hospitals that excel in a variety of difficult areas of care by conducting research, pioneering advanced treatments and bringing the best technology and expertise to bear. Just 176 hospitals scored high enough this year to rank in even a single area out of all 6007 U.S. medical centers, and only 16 accumulated enough points to make it to the Honor Roll reserved for medical centers that ranked at or near the top in at least six specialties. Hopkins placed #3 in Cancer, #1 in Gynecology, # 3 in Digestive Disorders. For a complete list of all rankings, go to www.usnews.com or www.hopkinsmedicine.org.
Development of Rare Esophageal Cancer in African-Americans May Differ from Whites posted May 10, 2004
The development of an aggressive but rare type of esophageal cancer in African-Americans may follow a different path than the same disease in whites, and is more likely to be fatal, according to results of a study by researchers at Johns Hopkins.
Whites who develop the cancer, called esophageal adenocarcinoma, usually develop an abnormal lining of their throat, a condition called Barrett's metaplasia, the researchers say. This is followed by a precancerous condition called dysplasia, and finally, cancer. However, African-Americans who develop esophageal adenocarcinoma were observed not to develop Barrett's metaplasia as frequently.
"Our finding is significant because it suggests that physicians should be alert to the fact that esophageal adenocarcinoma doesn't necessarily present identically in African Americans and whites," says Pierre R. Theodore, M.D., a fellow and resident in Johns Hopkins' Department of Surgery. "And though this cancer is rare in African-Americans, they have a worse rate of survival than do whites."
Theodore presented the results of this study this week at the 84th annual meeting of the American Association of Thoracic Surgeons in Toronto.
The Johns Hopkins researchers made their findings during a study of 574 patients with esophageal adenocarcinoma, of whom 3.5 percent (20/574) were African-American.
Compared to whites, African-Americans were significantly less likely to have Barrett's metaplasia -- the early form of esophageal adenocarcinoma. Specifically, 20 percent (4/20) of African-Americans had Barrett's metaplasia versus 57 percent of whites (317/554). Moreover, only 35 percent (7/20) of African Americans had a history of gastrointestinal reflux disease (GERD) versus 54 percent (301/554) of whites. GERD is a disorder in which stomach acid backs up into the esophagus, causing the
symptom of heartburn. Continued GERD can destroy the layer of tissue lining of the esophagus, which, in some cases, is replaced by cancerous tissue. Although a relatively small percentage of African-Americans compared to whites had the early signs of esophageal cancer -- GERD and Barrett's metaplasia -- 45 percent (9/20) of them had advanced stage disease compared with 22.2 percent (123/554) of whites, according to the Johns Hopkins team.
In addition, the overall survival rates in African-Americans were significantly worse than whites, with no African-Americans surviving more than three years.
The other authors of this report include Craig Hooker, Eric Syphard, Leonard Sowah, Arlene Forastiere, Elizabeth Montgomery, David Mason, James Herman, Stephen Yang and Malcolm V. Brock.
Grass Roots Fundraising
Fundraising events planned by grateful patients or users of this Website have raised money for Esophageal Cancer research at Johns Hopkins.
One such family, the Jeannottes, recently visited the Johns Hopkins
research facilities. They are in the process of organizing a Golf
Classic in memory of their husband & father, Roy L. Jeannotte.
Read More >
CHEMOPREVENTION TRIAL
The Johns Hopkins Medical Institution is the lead center in a multi-center National Cancer Institute sponsored chemoprevention trial in patients with Barrett’s-associated dysplasia. Patients who have either low or high grade dysplasia will be eligible to be randomized to take either a selective cyclooxygenase-2 (COX-2) inhibitor, celecoxib or placebo. Celecoxib or placebo will be taken twice a day. Celecoxib is currently available by prescription as an anti-inflammatory and analgesic drug. Read More >
|
| |
